On June 5, DotBio-B rose 6.03% in regular trading, trading at 194.3 HKD/share, with trading volume of approximately 58.48 million HKD.

On the news front, the company has conducted intensive share repurchases over the past three trading days from June 2 to June 4, buying back 64,500 shares, 37,100 shares, and 34,000 shares respectively, spending a combined total of approximately 27.23 million HKD. Simultaneously, the company announced on June 4 a proposal to authorize the repurchase of up to 10% of total issued shares, equivalent to approximately 9.04 million shares, further signaling management confidence in the stock.

Additionally, at the 2026 ASCO Annual Meeting, Phase 1a dose-escalation and safety expansion data for DB-1312/BG-C9074 (a B7-H4 ADC co-developed with BeiGene) in advanced solid tumors were presented via rapid oral report on June 2, providing clinical pipeline catalysts. The broader biotech sector also rallied, with Kelun-Biotech up 5.48%, Innovent Bio up 3.6%, and Akeso up 2.56%, creating positive sector sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)